Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Exemestane

Goserelin

Anastrozole

Aromatase Inhibitors

Antineoplastic Agents, Hormonal

Enzyme Inhibitors

Estrogens

Estrogen Antagonists

Estrogen Receptor Antagonists

Hormones

Hormone Antagonists

Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.

Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.

Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.

Patients will take anastrozole 1mg qd.

OFS + Anastrozole

Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.

OFS + Exemestane

Kunwei Shen, Professor

To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.

Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients

Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study

Bone and joint pains are measured by National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) classification v4.0 every 3 months.

Shanghai Jiao Tong University School of Medicine

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients	NCT02440230	Breast Cancer	OFS + Anastrozo... OFS + Exemestan...	18 Years -	Shanghai Jiao Tong University School of Medicine
Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients	NCT02440230	Breast Cancer	OFS + Anastrozo... OFS + Exemestan...	18 Years -	Shanghai Jiao Tong University School of Medicine

Spots Global Cancer Trial Database for ofs + anastrozole